Neoleukin Therapeutics (NLTX) Prices 8.925M Share Offering at $8.40/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering
December 17, 2019 10:25 PM ESTSEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (Neoleukin) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the pricing of an underwritten public offering of 8,925,000 shares of its common stock at a price to the public of $8.40 per share. The aggregate gross proceeds from this offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Neoleukin. The offering is expected to close on or about December 20, 2019, subject to customary closing conditions. Neoleukin has... More
